Mereo BioPharma (MREO) Share-based Compensation (2023 - 2026)

Mereo BioPharma (MREO) has reported Share-based Compensation for 4 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation rose 141.44% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (down 27.79% YoY) and the FY2025 annual result came in at $7.6 million, up 2.81% from the prior year.
• Share-based Compensation improved to $5.5 million in Q1 2026 per MREO's latest filing, from $1.5 million in the prior quarter.
• Over the last five years, Share-based Compensation for MREO reached as high as $6.9 million in Q2 2025 and fell as low as $815000.0 in Q4 2023.
• A 4-year average of $2.6 million and a median of $1.7 million in 2024 frame the typical range for Share-based Compensation.
• The largest YoY upside for Share-based Compensation was 230.46% in 2025 against a maximum downside of 1.85% in 2025.
• Year by year, Share-based Compensation stood at $815000.0 in 2023, then jumped by 85.89% to $1.5 million in 2024, then advanced by 1.85% to $1.5 million in 2025, then jumped by 256.45% to $5.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $5.5 million, $1.5 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.